US court confirms protection for Pfizer's Lyrica until 2018, hitting ANDA challenges
This article was originally published in Scrip
Pfizer secured patent protection through to the end of 2018 for Lyrica (pregabalin) on 19 July when a US federal court judge said that the patents licensed from Northwestern University were valid and infringed by Teva Pharmaceuticals' and other manufacturers' US abbreviated new drug applications (ANDAs) for a generic formulation of the blockbuster pain drug.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.